A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

NCT00002155 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Indinavir sulfate
DRUG: Lamivudine
DRUG: Zidovudine

Sponsor

Merck Sharp & Dohme LLC